Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and…
NWEA MAP®, STAR®, aReading, AUTOreading, and WIST Results Reflect Gains in Reading and Language SkillsJACKSONVILLE, Fla., Jan. 29, 2026 /PRNewswire/…
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to…
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies…
Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and…
MIDDLETON, Wis., Jan. 28, 2026 /PRNewswire/ -- Natus Medical Incorporated announces the launch of the newest version of its industry-leading…
- TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in…
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trialsBOSTON, Jan. 28,…
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™…
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of…